---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-132088"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2021-11-01T23:59:59+00:00"
generated_at: "2026-06-28T15:48:50.331851+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kiniksa reports Q3 ARCALYST net revenue of $12.1M; net loss narrows to $30.5M

## Summary
- ARCALYST net revenue $12.1M in Q3 2021; Q4 2021 revenue guided to $16-17M.
- Net loss of $30.5M improved from $43.8M in Q3 2020; operating expenses $42.8M.
- Cash and investments $200.2M, no debt; cash expected to fund operations into 2023.
- Mavrilimumab Phase 3 in COVID-19 ARDS data expected Q1 2022; vixarelimab Phase 2b data in prurigo nodularis expected 2H 2022.
- Over 200 physicians prescribed ARCALYST for recurrent pericarditis since approval; >190M lives covered.

## SEC filing metadata
- accession: 0001104659-21-132088
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2021-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465921132088/0001104659-21-132088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465921132088/tm2131179d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-132088
- JSON: https://secwatch.observer/filing/0001104659-21-132088.json
- Plain text: https://secwatch.observer/filing/0001104659-21-132088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.